Maria Trojano, full professor of Neurology at the “Aldo Moro” University of Bari, explains the characteristics of Ofatumumab, the first highly effective home treatment targeted at B cells indicated for adults with relapsing remitting multiple sclerosis in which the patient has exacerbations followed by periods with milder or no symptoms.